Phase 1/2a Study of JAB-21822 Plus JAB-3312 in Patients With Advanced Solid Tumors Harboring KRAS p.G12C Mutation

Clinical trial NCT05288205 · RECRUITING

Trial details

NCT number: NCT05288205
Sponsor: Allist Pharmaceuticals, Inc.
Status: RECRUITING
Phase: Phase 1, Phase 2
Study type: INTERVENTIONAL

KRAS P.G12C Non-small Cell Lung Cancer Colorectal Cancer Pancreatic Ductal Carcinoma

Start date: 2022-04-14
Primary completion: 2027-03-01
Enrollment: 240

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.